
Gibson, Dunn & Crutcher LLP’s life sciences practice represents biotech, pharma, and medical device companies in IP and corporate and commercial transactions. The firm has a strong transactional team advising both issuers and financial institutions in deals across M&A, venture financing, stock and asset acquisitions, and private and public securities offerings. Its patent litigation expertise includes cases under the Hatch-Waxman Act, as well as the enforcement of second- and third-generation, combination drug, and formulation patents. The practice is co-chaired by San Francisco’s Ryan Murr, who is vastly experienced in capital markets transactions, M&A, royalty financing, and corporate governance. Also co-chair, New York-based Jane Love handles high-value patent litigation, patent prosecution, and diligence advice connected to transactions.
Legal 500 redaktioneller Kommentar
Auszeichnungen
Mandantenzufriedenheit
Kernmandanten
- Merck and Organon
- Dental Monitoring SAS
- MedinCell
- Merck & Co.
- Royalty Pharma
- Epygenix Therapeutics, Inc.
- Apogee Therapeutics, Inc.
- Ultragenyx Pharmaceutical Inc.
- Arrowhead Pharmaceuticals, Inc.
- Alcon Inc.
Anwält*innen
Führende Partner*innen
Die stärksten Partner*innen ihres Praxisbereichs, die eine führende Rolle in signifikanten Mandaten einnehmen und weitreichende Anerkennung unter Wettbewerbern und Mandanten genießen.

Praxisleitung
Ryan Murr; Jane Love
Weitere Kernanwält*innen
Branden Berns; Karen Spindler; Chris Trester; Charlotte Jacobsen